Jinbo

Shanxi Jinbo Biopharmaceutical Co., Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and sale of recombinant humanized collagen products. Founded in March 2008 by Yang Xia, a former teacher at Shanxi Medical University, the company has become a key player in China's synthetic biology and collagen industry. Jinbo Biopharmaceutical achieved a significant milestone with the development and industrialization of recombinant humanized collagen, making China the first country to do so. The company was listed on the National Equities Exchange and Quotations (NEEQ) in July 2015 and later on the Beijing Stock Exchange on July 20, 2023.

The company's core business revolves around its proprietary functional proteins, primarily recombinant Type III humanized collagen and anti-HPV biological proteins. These materials are developed through advanced techniques like structural biology and protein engineering and are produced via biological fermentation, which avoids the risks associated with animal-derived products. The firm's product portfolio is segmented into medical devices, functional skincare products, and raw materials. Its offerings cater to various medical fields including dermatology, gynecology, and surgery, as well as the medical beauty and skincare markets. A key product is an injectable Recombinant Humanized Type III Collagen Solution, approved by China's NMPA for correcting facial wrinkles. The company's business model encompasses the entire industrial chain, from raw material research to the manufacturing and sale of finished products. Revenue is generated through the sale of these products to clients that include medical device and cosmetics companies.

Jinbo Biopharmaceutical places a strong emphasis on research and development, collaborating with institutions like Fudan University and Sichuan University. This focus has led to numerous patents and the atomic-level analysis of several protein structures, which have been included in the international Protein Data Bank (PDB). In June 2021, its injectable recombinant III-type humanized collagen lyophilized fiber was the first of its kind approved by the NMPA, a landmark achievement for the company.

Keywords: recombinant collagen, humanized collagen, biopharmaceuticals, medical devices, functional skincare, synthetic biology, protein engineering, injectable fillers, dermatology, anti-aging, biomedical materials, collagen production, NMPA approved, structural biology, Yang Xia, Beijing Stock Exchange